医学
慢性偏头痛
降钙素基因相关肽
偏头痛
内科学
单克隆抗体
打开标签
随机对照试验
单克隆
抗体
免疫学
受体
神经肽
作者
Abouch Valenty Krymchantowski,Carla Jevoux,Ana Gabriela Krymchantowski,Raimundo Pereira Silva‐Néto
出处
期刊:Clinical Neuropharmacology
[Ovid Technologies (Wolters Kluwer)]
日期:2023-06-20
卷期号:46 (5): 181-185
被引量:3
标识
DOI:10.1097/wnf.0000000000000559
摘要
Medication overuse headache (MOH) in chronic migraineurs may be a cause or consequence of the overuse of symptomatic medications for headache attacks. It is highly prevalent in tertiary centers. We compared the efficacy of 3 anti-CGRP monoclonal antibodies with traditional pharmacological agents in patients with chronic migraine (CM) and MOH.A randomized, cross-sectional, prospective, and open trial with real-world comparison groups was carried out. The sample consisted of 100 consecutive patients having CM and MOH.Eighty-eight patients (65 women and 23 men) were included in the study and divided into 4 groups: those having used erenumab (19.3%), galcanezumab (29.6%), fremanezumab (25%) and conventional medications, and the control group (26.1%). Ages ranged from 18 to 78 years (mean, 44.1 ± 13.6 years). In the 6 months of follow-up, there was a significant reduction in the number of headache days in the 3 groups when compared with the control (P < 0.0001).The small number of patients included in each group and the open design do not allow definitive conclusions, but the use of anti-CGRP monoclonal antibodies in patients with CM and MOH may result in lessening the number of headache days when compared with conventional treatment with drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI